How do you help an emerging biotech disclose highly anticipated Phase 3 results and demonstrate the value this therapy can potentially bring to patients?


  • Manage disclosure of pivotal Phase 3 data
  • Define clinical success in atopic dermatitis (AD)
  • Differentiate topical treatment from available and investigational therapies



  • Anticipated scenarios for Phase 3 outcomes
  • Crafted messages and news releases for each scenario
  • Produced materials to introduce company and its product to reporters
  • Designed infographics on unmet needs in AD and clinical trial design
  • Involved investigators and patient organization in data announcement


  • Widespread financial and media coverage of positive data
  • The company‚Äôs valuation more than doubled to nearly $6 billion
  • Maintained strong valuation following announcement

“If approved crisaborole could become a significant first-in-class treatment option for patients with mild-to-moderate atopic dermatitis.” – Amy Paller, MD, Northwestern University